Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|April 26, 2019
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b studyNoa Biran, David Siegel, Jesus G Berdeja, et al.
Blood Advances|October 14, 2021
A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasmPeng Li, Shobi Venkatachalam, Daniela Ospina Cordona, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 26, 2022
GABA-A Receptor Encephalitis After Autologous Hematopoietic Stem Cell Transplant forMultiple Myeloma: Three Cases and Literature ReviewYoji Hoshina, Jonathan Galli, Ka-Ho Wong, et al.
Molecular and Cellular Biology|January 31, 2003
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complexNils Holler, Aubry Tardivel, Magdalena Kovacsovics-Bankowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failedM J Keating, B Cazin, S Coutré, et al.
American Journal of Hematology|October 30, 2020
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myelomaMelissa Alsina, Ola Landgren, Noopur Raje, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective studyEmma C Scott, Stephen B Heitner, William Dibb, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2009
RNAi screen for rapid therapeutic target identification in leukemia patientsJeffrey W Tyner, Michael W Deininger, Marc M Loriaux, et al.
Pageof 11